Why the study?
What are the pharmacokinetics of rhIGF-I in adults with growth hormone deficiency compared to normal individuals?
What are the pharmacokinetics of rhIGF-I in adults with growth hormone deficiency compared to normal individuals?
Answers are grounded in this paper and cite their sources.
In adults with growth hormone deficiency, rhIGF-I has normal absorption and distribution but faster elimination kinetics, with bioavailability modulated by binding proteins.
We investigated the pharmacokinetics of recombinant human insulin-like growth factor I (rhIGF-I) in growth hormone deficiency (GHD). Nine GHD adults [age 25 +/- 3 (SE) yr] received rhIGF-I (60 microgram/kg sc) twice, 10 h apart, and blood was sampled over 24 h. IGF-I and free IGF-I concentrations increased, whereas IGF binding protein 3 (IGFBP-3) and acid labile subunit (ALS) were unchanged during treatment. There was no correlation between absorption or terminal half-life of IGF-I and IGFBP-3 or ALS, but negative correlations with IGF-I clearance (CL/F) and volume of distribution (V/F). Positive correlations between both IGFBP-3 and ALS and IGF-I maximal concentration (C(max)) and time of C(max) (T(max)) were observed. Compared with normal individuals studied similarly (using 80 microgram/kg), GHD subjects showed a normal absorption half-life, a faster elimination half-life, lower C(max), yet normal T(max) and V/F. In conclusion, GHD is associated with normal absorption and distribution of IGF-I yet faster elimination kinetics. Additionally, IGFBP-3 and ALS concentrations modulate the peak concentrations of IGF-I achieved and correlate reciprocally with its V/F and CL/F, underscoring the critical importance of binding proteins in modulating the bioavailability of IGF-I in vivo in humans.
No takes yet. Share an insight, caveat, or question.
Mauras et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: